Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab

Aiyin Chen, Thomas N. Hwang, Laura T. Phan, Timothy J. McCulley, Michael K. Yoon

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.

Original languageEnglish (US)
Pages (from-to)432-435
Number of pages4
JournalMiddle East African Journal of Ophthalmology
Volume19
Issue number4
DOIs
StatePublished - Oct 1 2012
Externally publishedYes

Fingerprint

Pseudolymphoma
B-Lymphocytes
Therapeutics
Monoclonal Antibodies
Rituximab

Keywords

  • Benign Reactive Lymphoid Hyperplasia
  • Rituximab
  • Systemic

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab. / Chen, Aiyin; Hwang, Thomas N.; Phan, Laura T.; McCulley, Timothy J.; Yoon, Michael K.

In: Middle East African Journal of Ophthalmology, Vol. 19, No. 4, 01.10.2012, p. 432-435.

Research output: Contribution to journalArticle

Chen, Aiyin ; Hwang, Thomas N. ; Phan, Laura T. ; McCulley, Timothy J. ; Yoon, Michael K. / Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab. In: Middle East African Journal of Ophthalmology. 2012 ; Vol. 19, No. 4. pp. 432-435.
@article{41fda60063a3496d8c3c79fa47119f79,
title = "Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab",
abstract = "Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.",
keywords = "Benign Reactive Lymphoid Hyperplasia, Rituximab, Systemic",
author = "Aiyin Chen and Hwang, {Thomas N.} and Phan, {Laura T.} and McCulley, {Timothy J.} and Yoon, {Michael K.}",
year = "2012",
month = "10",
day = "1",
doi = "10.4103/0974-9233.102770",
language = "English (US)",
volume = "19",
pages = "432--435",
journal = "Middle East African Journal of Ophthalmology",
issn = "0974-9233",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "4",

}

TY - JOUR

T1 - Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab

AU - Chen, Aiyin

AU - Hwang, Thomas N.

AU - Phan, Laura T.

AU - McCulley, Timothy J.

AU - Yoon, Michael K.

PY - 2012/10/1

Y1 - 2012/10/1

N2 - Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.

AB - Rituximab, a monoclonal antibody to the B cell marker CD20, is becoming increasingly popular in the treatment of various orbital disorders. In this university-based interventional case series, we describe two patients with bilateral orbital and extra-orbital reactive lymphoid hyperplasia (RLH) treated with rituximab. Initially both had favorable responses; but roughly a year later recurrent disease necessitated maintenance therapy in both cases. Both again responded to additional courses of rituximab. Although recalcitrant disease may persist after treatment, rituxmab may play a role in the management of RLH with widespread involvement.

KW - Benign Reactive Lymphoid Hyperplasia

KW - Rituximab

KW - Systemic

UR - http://www.scopus.com/inward/record.url?scp=84870214203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870214203&partnerID=8YFLogxK

U2 - 10.4103/0974-9233.102770

DO - 10.4103/0974-9233.102770

M3 - Article

C2 - 23248552

AN - SCOPUS:84870214203

VL - 19

SP - 432

EP - 435

JO - Middle East African Journal of Ophthalmology

JF - Middle East African Journal of Ophthalmology

SN - 0974-9233

IS - 4

ER -